MONONA, Wis. – July 3, 2013 SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has received notice that the Nuclear Regulatory Commission (NRC) has accepted the first part of its Construction Permit application for review and docketing. This is the first formal step by the NRC in the construction permitting process for the SHINE medical isotope facility in Janesville, Wisconsin.
As required by Federal regulations, the Construction Permit application consists of general information about SHINE, an analysis of environmental impacts from the construction and operation of the facility, if any, and a preliminary safety analysis of the planned facility. Today’s acceptance for review and docketing includes the environmental analysis and general and financial information about SHINE; the remaining portions of the preliminary analysis were filed with the NRC on May 31st and will be reviewed for acceptance over the next couple of months.
The NRC’s permitting process is expected to take approximately eighteen months.
“The docketing and acceptance of our application is an important milestone, as it means that the application is of high enough quality for the complete review” said SHINE CEO and founder Greg Piefer.